Evidence map›Paper›PMID 31686768›Full record

Trial reportWorld journal of gastroenterology2019

Prebiotic UG1601 mitigates constipation-related events in association with gut microbiota: A randomized placebo-controlled intervention study.

Jae Ryang Chu, Saem-Yi Kang, Sung-Eun Kim, Sol-Ji Lee, Young-Chul Lee, Mi-Kyung Sung

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 71 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Journal of traditional and complementary medicine · 2025
    Article
  6. Article
  7. Review
  8. Treatment of constipation withChinese herbal medicines · 2024
    Review
  9. Review
  10. Article
  11. Assessing the causal effects ofFrontiers in microbiology · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jae Ryang ChuDepartment of Food and Nutrition, Sookmyung Women's University, Seoul 04310, South Korea.
Saem-Yi KangDepartment of Food and Nutrition, Sookmyung Women's University, Seoul 04310, South Korea.
Sung-Eun KimDepartment of Food and Nutrition, Sookmyung Women's University, Seoul 04310, South Korea.
Sol-Ji LeeDepartment of Food and Nutrition, Sookmyung Women's University, Seoul 04310, South Korea.
Young-Chul LeeUnigen, Inc., Cheonan 31257, South Korea.
Mi-Kyung SungDepartment of Food and Nutrition, Sookmyung Women's University, Seoul 04310, South Korea. mksung@sookmyung.ac.kr.
Sookmyung Women's University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConstipation is a common functional gastrointestinal disorder and its etiology is multifactorial. Growing evidence suggests that intestinal dysbiosis is associated with the development of constipation. Prebiotics are subjected to bacterial fermentation in the gut to produce short-chain fatty acids (SCFAs), which can help relieve constipation symptoms. The prebiotic UG1601 consists of inulin, lactitol, and aloe vera gel, which are known laxatives, but randomized, controlled clinical trials that examine the effects of this supplement on gut microbiota composition are lacking.

aimTo assess the efficacy of the prebiotic UG1601 in suppressing constipation-related adverse events in subjects with mild constipation.

methodsAdults with a stool frequency of less than thrice a week were randomized to receive either prebiotics or a placebo supplement for 4 wk. All participants provided their fecal and blood samples at baseline and at the end of intervention. Gastrointestinal symptoms and stool frequency were evaluated. The concentrations of serum endotoxemia markers and fecal SCFAs were determined. The relative abundance of SCFA-producing bacteria and the gut microbial community in the responders and non-responders in the prebiotics supplementation group were evaluated.

resultsThere were no significant differences in gastrointestinal symptoms between groups, although the prebiotic group showed greater symptom improvement. However, after prebiotic usage, serum cluster of differentiation (CD) 14 and lipopolysaccharide (LPS) concentrations were significantly decreased (CD14,

conclusionAlterations in gut microbiota composition, including a decrease in the phylum Firmicutes and an increase in butyrate-producing bacteria, following prebiotic UG1601 supplementation might help alleviate symptom scores and endotoxemia.

Indexed as

AdultConstipationDouble-Blind MethodDysbiosisEndotoxemiaEubacterialesFatty Acids, VolatileFecesFemaleGastrointestinal MicrobiomeHumansInulinMaleMiddle AgedPlacebosPlant PreparationsAloe vera gelFatty Acids, VolatileInulinlactitolPlacebosPlant PreparationsPrebioticsSugar AlcoholsConstipationEndotoxemiaGut microbiotaPrebioticsShort-chain fatty acids

Identifiers

PMID31686768
PMCPMC6824284
OpenAlexW2981887278

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.